Старый друг лучше новых двух, или «Золотой стандарт» ингибитора ангиотензинпревращающего фермента

1. Задионченко В.С., Ялымов А.А., Шехян Г.Г. и др. Место каптоприла в терапии сердечно-сосудистых заболеваний. Справочник поликлинического врача. 2017; 1: 70–5. / Zadionchenko V.S., Ialymov A.A., Shekhian G.G. i dr. Place of captopril in the therapy of cardiovascular diseases. Handbook for Practitioners Doctors. 2017; 1: 70–5. [in Russian]
2. Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute MI: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Chin Med J 1997; 110: 834–8.
3. Денисова А.Г., Татарченко И.П., Позднякова Н.В. Структурно-геометрические показатели левого желудочка в оценке электрического ремоделирования сердца при сахарном диабете. Доктор.Ру. 2016; 11 (128): 36–41. / Denisova A.G., Tatarchenko I.P., Pozdniakova N.V. Strukturno-geometricheskie pokazateli levogo zheludochka v otsenke elektricheskogo remodelirovaniia serdtsa pri sakharnom diabete. Doktor.Ru. 2016; 11 (128): 36–41. [in Russian]
4. Hansson L, Lindholm LH et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
5. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77.
6. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58.050 patients with suspected acute MI. Lancet 1995; 345: 669–85.
7. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
8. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
9. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
10. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
11. Верткин А.Л., Тополянский А.В. Гипертонический криз. Врач скорой помощи. 2013; 3: 22–30. / Vertkin A.L., Topolianskii A.V. Gipertonicheskii kriz. Vrach skoroi pomoshchi. 2013; 3: 22–30. [in Russian]
12. Верткин А.Л., Ховасова Н.О. Гипертонический криз: неотложная помощь в поликлинике. Амбулаторный прием. 2015; 1 (1): 13–7. / Vertkin A.L., Khovasova N.O. Gipertonicheskii kriz: neotlozhnaia pomoshch' v poliklinike. Ambulatornyi priem. 2015; 1 (1): 13–7. [in Russian]
13. Тагирова Г.А., Нагибин С.И., Семенова К.А., Болотнова Т.В. Особенности гипертонических кризов у лиц пожилого возраста, тактика врача первичного звена. Тюменский мед. журн. 2015; 17 (2): 19–21. / Tagirova G.A., Nagibin S.I., Semenova K.A., Bolotnova T.V. Osobennosti gipertonicheskikh krizov u lits pozhilogo vozrasta, taktika vracha pervichnogo zvena. Tiumenskii med. zhurn. 2015; 17 (2): 19–21. [in Russian]
14. Яковлев Л.Ю., Ручкин И.В., Чупандина Е.Е. Анализ регионального рынка ингибиторов АПФ (на примере Воронежской области). Вестн. ВГУ. 2014; 2: 132–6. / Iakovlev L.Iu., Ruchkin I.V., Chupandina E.E. Analiz regional'nogo rynka ingibitorov APF (na primere Voronezhskoi oblasti). Vestn. VGU. 2014; 2: 132–6. [in Russian]
15. Журавлев Д.А., Бочанова Е.Н., Богданов В.В. Анализ стоимости лечения первичной артериальной гипертензии в Красноярском крае в условиях лекарственного страхования. Сибирское мед. обозрение. 2014; 4: 82–5. / Zhuravlev D.A., Bochanova E.N., Bogdanov V.V. Analiz stoimosti lecheniia pervichnoi arterial'noi gipertenzii v Krasnoiarskom krae v usloviiakh lekarstvennogo strakhovaniia. Sibirskoe med. obozrenie. 2014; 4: 82–5. [in Russian]
16. Stokes J, Kannel W, Wolf P et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study – 30 years of follow-up. Hypertension 1989; 13 (5 Suppl.): 13–8.
17. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Pressure 2001; 10: 62–73.

________________________________________________

1. Zadionchenko V.S., Ialymov A.A., Shekhian G.G. i dr. Place of captopril in the therapy of cardiovascular diseases. Handbook for Practitioners Doctors. 2017; 1: 70–5. [in Russian]
2. Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute MI: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Chin Med J 1997; 110: 834–8.
3. Denisova A.G., Tatarchenko I.P., Pozdniakova N.V. Strukturno-geometricheskie pokazateli levogo zheludochka v otsenke elektricheskogo remodelirovaniia serdtsa pri sakharnom diabete. Doktor.Ru. 2016; 11 (128): 36–41. [in Russian]
4. Hansson L, Lindholm LH et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
5. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77.
6. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58.050 patients with suspected acute MI. Lancet 1995; 345: 669–85.
7. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
8. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
9. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
10. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
11. Vertkin A.L., Topolianskii A.V. Gipertonicheskii kriz. Vrach skoroi pomoshchi. 2013; 3: 22–30. [in Russian]
12. Vertkin A.L., Khovasova N.O. Gipertonicheskii kriz: neotlozhnaia pomoshch' v poliklinike. Ambulatornyi priem. 2015; 1 (1): 13–7. [in Russian]
13. Tagirova G.A., Nagibin S.I., Semenova K.A., Bolotnova T.V. Osobennosti gipertonicheskikh krizov u lits pozhilogo vozrasta, taktika vracha pervichnogo zvena. Tiumenskii med. zhurn. 2015; 17 (2): 19–21. [in Russian]
14. Iakovlev L.Iu., Ruchkin I.V., Chupandina E.E. Analiz regional'nogo rynka ingibitorov APF (na primere Voronezhskoi oblasti). Vestn. VGU. 2014; 2: 132–6. [in Russian]
15. Zhuravlev D.A., Bochanova E.N., Bogdanov V.V. Analiz stoimosti lecheniia pervichnoi arterial'noi gipertenzii v Krasnoiarskom krae v usloviiakh lekarstvennogo strakhovaniia. Sibirskoe med. obozrenie. 2014; 4: 82–5. [in Russian]
16. Stokes J, Kannel W, Wolf P et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study – 30 years of follow-up. Hypertension 1989; 13 (5 Suppl.): 13–8.
17. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Pressure 2001; 10: 62–73.

Г.Ю.Кнорринг, А.Л.Верткин*

ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*kafedrakf@mail.ru

________________________________________________

G.Yu.Knorring, A.L.Vertkin*

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*kafedrakf@mail.ru